News: prostate cancer
International PacRim Breast and Prostate Cancer Meeting – 2024
In 2024, we will be celebrating the 21st anniversary of the International Pacific Rim (PacRim) Breast and Prostate Cancer Meeting series, twenty-one years after the inaugural PacRim Meeting was held in southern Australia.
[Read more about International PacRim Breast and Prostate Cancer Meeting – 2024]
DRMCRL research presented at the 3rd Nuclear Receptors Conference, 4 -7 May 2022
DRMCRL Director, Prof Wayne Tilley and Prof Charlotte Bevan (Imperial College London) co-chaired the 3rd Nuclear Receptor meeting, which returned to a face to face format in Cancun, Mexico, after being postponed for the last two years.
[Read more about DRMCRL research presented at the 3rd Nuclear Receptors Conference, 4 -7 May 2022]
Associate Professor Alex Swarbrick presented at the Adelaide Medical School Distinguished Speaker Series 2022
Associate Professor Alex Swarbrick, Senior Principal Research Fellow and co-leader of the Strategic program in Dynamic Cancer Ecosystems, Garvan Institute of Medical Research, Sydney presented a seminar entitled "Solid tumours as cellular ecosystems: new insights into disease stratification and treatment", on 7 April, 2022, in the AHMS Building, University of Adelaide. The seminar covered how new technologies, including single cell sequencing and high-dimensionality tissue analysis, are enabling new insights into cancer ecosystems, leading to advances in the stratification and treatment of solid cancers. A/Prof Swarbrick is a developmental biologist with a long-standing interest in how cells in developing embryos control the decision to divide or to differentiate in co-ordination with cell cycle events, as well as how this co-ordination is subverted in cancers. The seminar was hosted by Prof Wayne Tilley, DRMCRL Director.
Prof Tilley contributes to the US Prostate Cancer Foundation Retreat: State of Science Report.
Research from Prof Tilley’s laboratory on “Nuclear receptor biology in castration resistant prostate cancer” was presented at the 28th Annual Prostate Cancer Foundation (PCF) Scientific Retreat, Carlsbad, USA in November, 2021. In a session that focused on nuclear receptor biology, including the role of GR in CRPC and its potential as a therapeutic target, as well as the impact of AR agonism in prostate cancer and ER-positive breast cancer, Prof Tilley presented data that suggested a role for potent AR agonists and that warranted further study into the potential for selective AR modulators in the treatment of breast and prostate cancer. His paper formed part of the PCF’s State of Science Report. In addition, the PCF Retreat Scientific Meeting Report will be published in the scientific journal, The Prostate.
DRMCRL researchers attend 34th Annual Lorne Cancer Conference 2022
Professor Wayne Tilley, Associate Professor Theresa Hickey and Dr Amy Dwyer attended the 2022 Annual Lorne Cancer Conference (https://www.lornecancer.org/) held at the Mantra Lorne. Assoc Prof Hickey gave a first session talk on "The androgen receptor as a therapeutic target in breast cancer", and Amy gave a Flash Talk on "High throughput cell morphology-based drug-screens in breast and prostate cancer reveals novel AR agonists". Both presentations were very well received.
[Read more about DRMCRL researchers attend 34th Annual Lorne Cancer Conference 2022]
Another DRMCRL student awarded PhD degree – Congratulations Reza Alizadeh Ghodsi!
Mohammadreza (Reza), our final student from the “2017 PhD quartet”, has been awarded a doctoral degree for his work on "Extreme activation of androgen receptor for prostate cancer therapy". Reza will continue prostate cancer research as a postdoc at the Fred Hutchinson Cancer Centre in Seattle, USA, in the laboratory of Dr Peter Nelson whose interests are in exploiting cancer genomics and the tumor microenvironment to guide oncology treatment. All the best and well done Reza!
[Read more about Another DRMCRL student awarded PhD degree – Congratulations Reza Alizadeh Ghodsi! ]
Symposium: Patient-derived in vitro models - Advances and challenges
Dr Jean Winter gave a presentation on "Advances and challenges of high-throughput 3D imaging using patient derived samples" as related to her breast cancer research, at the symposium organised by the South Australian Cancer Research Institute / University of South Australia. This focused symposium attracted more than 110 participants from 17 universities and research institutes across the country. Models and enabling technologies featured in the program were prostate cancer explants, and organoids derived from liver, nasal cells, ovary, breast and bowel cancer.
[Read more about Symposium: Patient-derived in vitro models - Advances and challenges]
Movember- National Breast Cancer Foundation Collaborative Linkage Program engagement meeting held in Sydney
Our Collaborative Linkage grant team members met in Sydney on 10 March 2020 to showcase and discuss the progress on our research program in "Transforming endocrine therapy for breast and prostate cancer". Representatives from each of the project’s node at the University of Adelaide, Monash University and the Garvan Institute attended in person or via teleconference, as did our funding sponsors, Movember and NBCF, and some of our consumer advocates.
Rayzel Fernandes - PhD conferral
Congratulations to Rayzel Fernandes on the conferral of her doctoral degree entitled “The role of microRNA-194 in prostate cancer progression”. Rayzel’s project was supported by an International Postgraduate Research Scholarship/ Australian Postgraduate Award, as well as a Freemason’s Foundation Centre for Men’s Health PhD Scholarship top-up award. Rayzel will be leaving the DRMCRL to take up a post-doctoral position at Imperial College London.
Dr Jean Winter speaks at the 10th Functional High Throughput Technologies Australia meeting
Dr Winter was invited to present her work on “High throughput drug screening in breast and prostate cancer using an innovative cell morphology-based analytical pipeline” at the 10th Functional High Throughput Technologies Australia meeting held at the John Curtin School of Medical Research, ANU, Canberra on 30-31 October.
